5-year EFS rate 95.2%, 5-year OS rate 100%! Rituximab combined with LMB-containing chemotherapy regimen has outstanding efficacy in ≤ 18-year-old patient with primary mediastinal large B-cell lymphoma!

• Baseline characteristics of the patient

In the LMB2001 trial, a total of 42 patients were registered as large B-cell lymphoma with the mediastinum as the main site, and the median age at diagnosis of these patients was 15 years (range: 8-18), 57% were female, and the baseline characteristics of the patients were shown in Table 2
.

Table 2

• efficacy

All patients received LMB-containing chemotherapy, including 19 patients in group B, 18 patients in group C, and 5 patients
in group B/C with modified LMB therapy.
After 2008, 21 patients received rituximab (R+) and 21 patients did not receive rituximab (R-).

The median follow-up was 7.
1 years (IQR: 5.
8-11.
1) for all patients, 10.
6 years for R- patients, and 6.
4 years
for R+ patients 。 A total of 5 events occurred, 1 with inadequate response and viable cells in residual masses (R- patient with complete remission [CR] after R-ICE [rituximab, ifosfamide, carboplatin, etoposide], BEAM [carmustine, etoposide, cytarabine, melphalan], autologous hematopoietic stem cell transplantation [ASCT], and radiation therapy [CR] and 3 patients with disease progression (2 R-, 1 R+), and 1 relapse (R-, Patients obtain CR2 and maintain it) (Table 3).

Table 3

A total of 2 patients died, both of which progressed
during rituximab therapy.
The 5-year EFS rate was 88.
1% (95% CI: 75.
0-94.
8) for all patients (Figure 1), 81.
0% (95% CI: 60.
0-92.
3) for R- patients, and 95.
2% (95% CI: 77.
3-99.
2) for R+ patients (HR: 0.
24, 95% CI: 0.
03-2.
2) (Figure 2A).

。 The 5-year OS rate was 95.
2% (95% CI: 84.
0-98.
7) for all patients (Figure 1), 90.
5% (95% CI: 71.
1-97.
3) for R- patients, and 100% for R+ patients (Figure 2B).

Figure 1

Figure 2